Información del artículo
En este artículo se especifica el protocolo unificado de utilización de hormona de crecimiento en pacientes adultos deficitarios: indicaciones para el inicio de tratamiento, diagnóstico bioquímico de la deficiencia de GH, contraindicaciones al tratamiento, dosis recomendadas y seguimiento.
Palabras clave:
Hormona del crecimiento
GH
Adultos deficitarios
Enfermedad hipotálamo-hipofisaria
Hipoglucemia insulínica
GHRP-6
IGF-1
Tratamiento GH
In this paper, we present the unified protocol for growth hormone therapy in adult patients with GH deficiency: treatment indications, biochemical diagnosis of GH deficiency, contraindications, recommended doses and follow-up.
Key words:
Growth hormone
GH
Adults with GH deficiency
Hypothalamic-pituitary dysfunction
Insulin-induced hypoglycemia
GHRP-6
IGF-1
GH treatment
El Texto completo está disponible en PDF
Biblografía General
[Abs, et.al, 1999]
R. Abs, B.A. Bengtsson, E. Hernberg-Stahl, J.P. Monson, J.P. Tauber, P. Wilton, et al.
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
Clin Endocrinol (Oxf), 50 (1999), pp. 703-713
[Bengtsson, et.al, 2000]
B.A. Bengtsson, G. Johannsson, S.M. Shalet, H. Simpson, P.H. Sonken.
Treatment of growth hormone deficiency in adults.
J Clin Endocrinol Metab, 85 (2000), pp. 933-942
[Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency, et.al, 1998]
Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency.
J Clin Endocrinol Metab, 83 (1998), pp. 379-381
[Díez, 2000]
J.J. Díez.
El síndrome de deficiencia de hormona del crecimiento en adultos: criterios actuales para el diagnóstico y tratamiento.
Med Clin (Barc), 114 (2000), pp. 468-477
[Drake, et.al, 2001]
W.M. Drake, S.J. Howell, J.P. Monson, S.M. Shalet.
Optimizing GH therapy in adults and children.
Endocr Rev, 22 (2001), pp. 425-450
[Le Roith, 1999]
D. Le Roith.
Although both rhGh and rhIGF-I have the potential to provide clinical benefit, each also has the potential to produce unwanted side-effects.
Growth Horm IGF Res, 9 (1999), pp. 83-84
[Popovic, et.al, 2002]
V. Popovic, S. Pekic, M. Simic, S. Damjanovic, D. Micic, C. Diéguez, et al.
Physical activity or food intake prior to testing did not affect the reproducibility of GH secretion elicited by GH releasing hormone plus GH-releasing hexapeptide in normal adult subjects.
Clin Endocrinol (Oxf), 56 (2002), pp. 89-94
[Rahim, et.al, 1996]
A. Rahim, A. Toogood, S.M. Shalet.
The assessment of growth hormone status in young males using a variety of provocative agents.
Clin Endocrinol (Oxf), 45 (1996), pp. 557-562
[Sanmartí and 2002]
A. Sanmartí.
Características clínicas y tratamiento con hormona del crecimiento en la persona mayor con déficit adquirido en la edad adulta.
Endocrinol Nutr, 49 (2002), pp. 13-15
[Shalet, et.al]
Shalet SM, Toogood A, Rahim A, Brennan BM. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición
